# Cosomil

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cosomil

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.cosomil.com
- Latest round: Series A (Feb 6, 2026)
- Investors on record: 5

## About

Based in Tokyo, Japan, and founded in 2022, Cosomil, Inc. d.b.a Cosomil operates as a biotechnology company that performs research and develops liquid biopsy technologies. The company was Co-founded by Kagamiyu (CEO), Sakamoto Shingo (CTO), Toru Komatsu, and Rikiya Watanabe. In February 2026, Cosomil raised an undisclosed amount in series A funding led by  Delight Ventures with participation from other investors Animal Spirits, Gogin Capital, ANRI and GREEN CORE.

The company develops testing technology for medical treatments. It develops liquid biopsy technologies that can assist in the early detection of cancers and other illnesses. The firm develops healthcare solutions using fluorescent enzyme substrates and microdevices.

The company plans to use the February 2026 funding to accelerate the R&D and practical deployment of its single-molecule liquid biopsy–based cancer screening tests in Japan and the United States.

## Funding rounds

- Series A, Feb 6, 2026 — Gogin Capital, ANRI, Delight Ventures, GREEN CORE, Animal Spirits

## Investors

- Gogin Capital — Series A
- ANRI (https://capitalatlas.ai/funds/anri) — Series A
- Delight Ventures (https://capitalatlas.ai/funds/delight-ventures) — Series A
- GREEN CORE — Series A
- Animal Spirits (https://capitalatlas.ai/funds/animal-spirits) — Series A